Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes-Six-Months Results from the Real-World STEMT Trial

被引：0
|
作者：
Mertens, Jonathan
de Winter, Hennah T.
Mazlom, Hadi
Peiffer, Frida W.
Dirinck, Eveline L.
Bochanen, Niels
Van Gaal, Luc F.
de Block, Christophe
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-751-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
751-P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study
    Shi, Chenyang
    Tan, Yijiong
    Hu, Shanshan
    Qin, Yingyi
    Tang, Yuanjun
    Wang, Yufan
    Fan, Guorong
    DIABETES OBESITY & METABOLISM, 2024, 26 (06): : 2513 - 2516
  • [42] Effect of Oral Semaglutide in Glycemic Control and Weight Reduction for People with Type 2 Diabetes Mellitus Having a BMI ≥25 kg/m2-A Six-Month Real-World Study
    Kesavadev, Jothydev
    Shankar, Arun
    Saboo, Banshi D.
    Ashik, Asha
    Naina, Junaid
    Jothydev, Krishnadev
    Basanth, Anjana
    Raj, Sourav K.
    Jothydev, Sunitha
    DIABETES, 2024, 73
  • [43] Above-Average Weight Loss at 1 Year Co-occurs with HbA1c Reduction in Patients with Type 2 Diabetes Treated with Exenatide Once-Weekly in a Real-World Setting
    Mcadam-Marx, Carrie
    Hiep Nguyen
    Schauerhamer, Marisa
    Unni, Sudhir
    Singhal, Mukul
    Cobden, David
    DIABETES, 2015, 64 : A650 - A650
  • [44] Comparing the Real-World Effects of Once-Weekly Semaglutide and Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcomes, Health Care Resource Utilization, and Medical Costs in Individuals With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    de Havenon, Adam H.
    Tan, Xi
    Liang, Yuanjie
    Yedigarova, Larisa
    Noone, Josh
    Xie, Lin
    Inzucchi, Silvio E.
    STROKE, 2024, 55
  • [45] Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10
    Matthew Capehorn
    Yasmin Ghani
    Charlotte Hindsberger
    Pierre Johansen
    Esteban Jódar
    Diabetes Therapy, 2020, 11 : 1061 - 1075
  • [46] Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
    Kimura, Tomohiko
    Kubo, Masato
    Takahashi, Kaio
    Wamata, Ryo
    Iwamoto, Yuichiro
    Iwamoto, Hideyuki
    Katakura, Yukino
    Sanada, Junpei
    Fushimi, Yoshiro
    Shimoda, Masashi
    Tatsumi, Fuminori
    Nakanishi, Shuhei
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    JOURNAL OF DIABETES RESEARCH, 2024, 2024
  • [47] Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10
    Capehorn, Matthew
    Ghani, Yasmin
    Hindsberger, Charlotte
    Johansen, Pierre
    Jodar, Esteban
    DIABETES THERAPY, 2020, 11 (05) : 1061 - 1075
  • [48] Taspoglutide, a once-weekly human GLP-1 analog, as monotherapy significantly lowers HbA1c and body weight in patients with type 2 diabetes: results from the T-emerge 1 phase 3 trial
    Raz, I.
    Fonseca, V. A.
    Kipnes, M. S.
    Durrwell, L.
    Hoekstra, J.
    Boldrin, M.
    Balena, R.
    DIABETOLOGIA, 2010, 53
  • [49] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)-Experienced Adults with Type 2 Diabetes (T2D) Switching to Once-Weekly (OW) Semaglutide in a Real-World Setting-SURE Program Post Hoc Analysis
    Rudofsky, Gottfried
    Menzen, Markus
    Potier, Louis
    Catarig, Andrei-Mircea
    Clark, Alice
    Priyadarshini, Prachi
    Abreu, Cristina
    DIABETES, 2023, 72
  • [50] Taspoglutide, a once-weekly human GLP-1 analogue, is superior to Sitagliptin in improving glycaemic control and achieving weight loss in patients with type 2 diabetes: the T-emerge 4 Trial
    Chiasson, J. -L
    Leiter, L. A.
    Forti, A.
    Bergenstal, R. M.
    Woloschak, M.
    Boldrin, M.
    Balena, R.
    DIABETOLOGIA, 2010, 53
12345